Excited to announce that our team at Proxima (formerly VantAI) has raised $80M in new funding led by @DCVC, with @nvidia, Braidwell, @Roivant, @aixventureshq, Yosemite, Magnetic Ventures, Alexandria Venture Investments, @ModiVentures, and others. We are building the platform for rational design of proximity-based medicines, from molecular glues to PROTACs and beyond. Links: Bloomberg Exclusive: bit.ly/3LaM1Iw Press Release: bit.ly/4jJG6qI Website: proximabio.com/

Neo just got faster again. We have been running NVIDIA BioNeMo Inference Runtime, released today by @NVIDIAHealth, in production across our distillation and refolding pipelines. It gives Neo a 1.6 to 1.9x throughput gain on H100, and up to 3x on shorter inputs. Integration took a few hours. A coding agent using the BioNeMo agent skill wired it into Neo in one shot, despite an architecture that looks nothing like the reference models, and it has run nonstop since. More from the BioNeMo team: nvda.ws/46PDmlL

We’re rapidly expanding what is likely the largest bet on large scale structural data generation to unlock zero shot drug design. If you’re a proteomics scientist used to industrialized large scale settings in academia or industry, join our fantastic team in Boston!

Do you want to work at the frontier of structural and chemical proteomics? Interested in induced proximity-and in building the data engine for the next decade of therapeutic discovery? Proxima is looking for an exceptional, highly motivated Proteomics Scientist to help build the experimental feedback loop that enables our ML models to understand biology. Backed by DCVC and NVIDIA’s NVentures, you’ll work alongside computational biologists and ML scientists, with access to a large fleet of latest-generation Orbitrap Astral Zoom mass spectrometers in our Boston lab. Learn more and apply: jobs.ashbyhq.com/proxima/6e3…

Join us in Seoul on Tuesday, July 7th for an evening social hosted by @proximabio, @NVIDIAHealth, @DCVC, and @Terray_Tx. Enjoy an open bar, bites, and a curated group of researchers, founders, and investors at the intersection of AI x Bio. Spots are limited. RSVP here: luma.com/2g1rr4v6

Today, NVIDIA launches BioNeMo Agent Toolkit. Backed by a decade of R&D, it adds Nemotron, NemoClaw & OpenShell to turn scientific workflows into repeatable, agent-executable tasks. This gives any agent and AI platform the capability to synthesize knowledge, call models, reason & execute. nvidianews.nvidia.com/news/n…

Discovering proximity-based medicines means connecting many disciplines such as foundation model training, chemistry, biology, and proteomics. Powered by the NVIDIA BioNeMo Agent Toolkit, our AI agents tie these domains together, turning new biology into therapeutic hypotheses faster and moving promising programs toward patients sooner. We're proud to build that future alongside @NVIDIAHealth as they launch the BioNeMo Agent Toolkit at BIO 2026. Links: - BioNeMo Agent Toolkit GitHub Repo: bit.ly/43Qp8ja - Blogpost: bit.ly/4vssVPG

Heading to Rio for ICLR 2026 - DM me to meet up… and don’t miss our rooftop party with NVIDIA 🍹 🌅 We’re hiring!

The @proximabio team is thrilled to be at ICLR 2026 in Rio! We're hiring Researchers and we'll be at ICLR to meet in person. If you're pushing the boundaries of generative AI x Bio, we want to talk. Apply here and we will be in touch to schedule: bit.ly/4cihNOs

Join us for an evening social at ICLR, hosted by @proximabio and @NVIDIAHealth Rooftop bar, bites, and a curated room of researchers, founders, and engineers at the intersection of AI x Bio. Spots are limited. RSVP here: luma.com/AIxBio

Drug discovery has a scale problem. The complexes that govern signaling, regulation, and disease aren't single proteins, or even tidy pairs. They're sprawling assemblies of 10, 20, even 50+ subunits. The field is forced to sidestep that level of complexity, not for lack of interest, but for lack of tools. And yet, simulating cellular biology requires modeling the complexes and interactions these proteins form, not just individual proteins. NeoLink, @proximabio's proteomics platform, has experimentally mapped millions of protein-protein interactions across these higher-order complexes. Predicting their structures at this scale demanded something new. We built it with @NVIDIAHealth. By integrating NVIDIA's Fold-CP into our pipeline, we distribute computation for long biological sequences across multiple GPUs, removing the memory bottleneck that kept these complexes out of reach. New preprint out now with the NVIDIA BioNeMo team: bit.ly/4rDQnXA

We are adding world-class expertise to our Scientific Advisory Board at @proximabio Dr. Raymond Deshaies: co-inventor of PROTACs, National Academy of Sciences member, fmr SVP Global Research at Amgen Dr. Lyn Jones (@LynJonesChemBio): molecular glue leader, fmr Head of Chemical Biology at Pfizer, PI at Dana-Farber Dr. Juri Rappsilber (@RappsilberJuri): pioneer of cross-linking mass spectrometry, Chair of Bioanalytics at TU Berlin We're excited to tap their deep expertise in target biology, medicinal chemistry, and structural proteomics as we build the platform for rational design of proximity-based medicines. Press release: bit.ly/4d4dYwV

Thrilled to have @DCVC and @nvidia alongside us as we build the platform for proximity-based medicines. We're just getting started: multiple exciting announcements coming soon. If you want to work on frontier ML models and an unprecedented biological data generation engine, we'd love to hear from you: recruiting@proximabio.com

Big congrats @mmbronstein! “Seed” 😅 👏👏👏👏👏 🫡🇺🇸

Interactomics is biology’s next data frontier. To truly solve disease, we need to understand the dynamic interfaces proteins form, and learn how to edit them systematically. Enter Proxima! Thrilled to have DCVC, NVIDIA, and an incredible syndicate of partners joining us on this mission.

Incredibly excited to introduce Proxima, our next chapter. Frontier models and a phase-shifting data engine, backed by an amazing group of investors, to unlock one of the most exciting new classes of medicines - Proximity Modulators.

.@proximabio = progress: that's why @DCVC led the $80M seed we announced yesterday. Signed collaborations with J&J, Bristol Myers Squibb, and Blueprint Medicines (now in Sanofi) could bring in billions of dollars in upfront and milestone payments and royalties.

📢 The VantAI team is thrilled to be at NeurIPS 2025! 💥 If you’re interested in meeting with a member of our team for a coffee chat, drop your details at this link and we’ll follow up to schedule forms.gle/5SD1GK4bS24cKKrj7

We're thrilled to partner with @HaldaTx to expand the reach of their groundbreaking RIPTAC platform. Together, we're working to identify new therapeutic target-effector combinations that will help enable this innovative proximity-based approach to unlock new treatment possibilities across cancer and immune disorders. Read more: bit.ly/4monuwV

Neo just got much faster!💥 Working closely with @NVIDIAHealth, VantAI adopted #cuEquivariance, leading to massive speedups. Today's announcement is a big advancement for the field!